サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1422943

MRSA治療薬市場：MRSAタイプ、薬剤クラス別、疾患適応症、投与経路、流通チャネル、地域別、2024年～2032年

MRSA Drugs Market by MRSA Type (Hospital-Acquired, Community-Acquired ), Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 149 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
MRSA治療薬市場：MRSAタイプ、薬剤クラス別、疾患適応症、投与経路、流通チャネル、地域別、2024年～2032年
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のMRSA治療薬市場規模は2023年に38億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて3.11%の成長率（CAGR）を示し、2032年までに50億米ドルに達すると予測しています。抗生物質耐性株の増加、長期入院によるヘルスケア施設での多剤耐性菌への継続的な曝露、臨床試験数の増加が市場を牽引する主な要因のひとつです。

メチシリン耐性黄色ブドウ球菌（MRSA）は、抗生物質耐性の黄色ブドウ球菌株によって引き起こされる感染症で、一般に外科的処置を受けたり、静脈注射を受けたり、皮膚と皮膚を接触させたりした患者に発症します。MRSA治療薬は、メチシリン耐性黄色ブドウ球菌感染症に対する抗菌薬として使用され、黄色ブドウ球菌を死滅または抑制します。患者の細胞合成と免疫力を高めながら、病原体の作用を抑制します。最も一般的なMRSA治療薬は、トリメトプリム-スルファメトキサゾール、クリンダマイシン、ミノサイクリン、リネゾリド、ドキシサイクリンです。これらの薬剤は一般的に経口薬として使用され、通常7～10日間のコースで使用されます。MRSA感染症は病院や地域社会で発生する可能性があるため、MRSAの治療には、重症度に応じて経口薬や静脈内投与が行われることがあります。皮膚感染症、骨感染症、菌血症、さらには動物の人獣共通感染症など、さまざまなタイプの感染症の治療に使用できる多種多様なMRSA治療薬があります。

MRSA治療薬の市場動向：

抗生物質耐性株の市場開拓の増加は、市場の成長を促す重要な要因です。これは、世界レベルでの院内感染（HAI）の症例数の増加に起因しています。また、長期入院によるヘルスケア施設での多剤耐性菌への継続的な曝露が、二次的な院内感染の発生を招き、市場を促進しています。これに加えて、MRSA感染症を発症しやすい高齢者人口の増加が、市場に弾みをつけています。さらに、さまざまな形態の細菌感染に関する意識の高まりが、MRSA治療薬の普及につながっています。これに伴い、多くの製品イノベーション、臨床試験の増加、新薬のイントロダクションが市場に有利な成長機会をもたらしています。しかし、MRSA治療薬の新薬開発には高いコストがかかるため、市場の成長抑制要因となっています。その一方で、抗生物質耐性菌のスクリーニングのための臨床試験プログラムの増加とともに、さまざまな診断ツールの継続的な技術開発が、市場の明るい見通しを生み出しています。さらに、主なプレーヤーによる広範な研究開発（R&D）活動も市場を後押ししています。市場に貢献しているその他の要因としては、現在入手可能な製品に対するジェネリック医薬品の出現、オンラインおよびオフラインの組織化されたプラットフォームでの抗生物質の容易な入手、急速な都市化、医療費の増加などが挙げられます。

本レポートで扱う主な質問

  • 世界のMRSA治療薬市場はこれまでどのように推移し、今後どのように推移していくのか？
  • MRSA治療薬の世界市場における促進要因、抑制要因、機会は何か？
  • 主要な地域市場は？
  • 最も魅力的なMRSA治療薬市場はどの国か？
  • MRSAタイプ別の市場内訳は？
  • 薬剤クラス別の市場内訳は？
  • 疾患適応症別の市場内訳は？
  • 投与経路別の市場内訳は？
  • 販売チャネル別の市場内訳は？
  • 世界のMRSA治療薬市場の競争構造は？
  • MRSA治療薬の世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 MRSA治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：MRSAタイプ別

  • 院内感染型（HA-MRSA）
    • 市場動向
    • 市場予測
  • 市中感染型（CA-MRSA）
    • 市場動向
    • 市場予測

第7章 市場内訳：薬剤クラス別

  • リポペプチド
    • 市場動向
    • 市場予測
  • オキサゾリジノン
    • 市場動向
    • 市場予測
  • セファロスポリン
    • 市場動向
    • 市場予測
  • テトラサイクリン
    • 市場動向
    • 市場予測
  • 葉酸拮抗薬
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：疾患適応症別

  • 皮膚感染症
    • 市場動向
    • 市場予測
  • 骨・関節感染症
    • 市場動向
    • 市場予測
  • 菌血症
    • 市場動向
    • 市場予測
  • 動物感染症
    • 市場動向
    • 市場予測

第9章 市場内訳：投与経路別

  • 経口投与
    • 市場動向
    • 市場予測
  • 非経口投与
    • 市場動向
    • 市場予測

第10章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第11章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第12章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • Basilea Pharmaceutica Ltd
    • Crystal Genomics Inc.
    • Cumberland Pharmaceuticals Inc
    • Melinta Therapeutics Inc
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc
図表

List of Figures

  • Figure 1: Global: MRSA Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: MRSA Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: MRSA Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: MRSA Drugs Market: Breakup by MRSA Type (in %), 2023
  • Figure 5: Global: MRSA Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: MRSA Drugs Market: Breakup by Disease Indication (in %), 2023
  • Figure 7: Global: MRSA Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 8: Global: MRSA Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 9: Global: MRSA Drugs Market: Breakup by Region (in %), 2023
  • Figure 10: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: MRSA Drugs (Lipopeptides) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: MRSA Drugs (Lipopeptides) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: MRSA Drugs (Oxazolidinones) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: MRSA Drugs (Oxazolidinones) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: MRSA Drugs (Cephalosporin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: MRSA Drugs (Cephalosporin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: MRSA Drugs (Tetracycline) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: MRSA Drugs (Tetracycline) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: MRSA Drugs (Folate Antagonist) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: MRSA Drugs (Folate Antagonist) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: MRSA Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: MRSA Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: MRSA Drugs (Skin Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: MRSA Drugs (Skin Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: MRSA Drugs (Bone and Joint Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: MRSA Drugs (Bone and Joint Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: MRSA Drugs (Bacteremia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: MRSA Drugs (Bacteremia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: MRSA Drugs (Animal Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: MRSA Drugs (Animal Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: MRSA Drugs (Oral Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: MRSA Drugs (Oral Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: MRSA Drugs (Parenteral Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: MRSA Drugs (Parenteral Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: MRSA Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: MRSA Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: MRSA Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: MRSA Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Global: MRSA Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Global: MRSA Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: North America: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: North America: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: United States: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: United States: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Canada: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Canada: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Asia-Pacific: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Asia-Pacific: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: China: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: China: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Japan: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Japan: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: India: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: India: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: South Korea: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: South Korea: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Australia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Australia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Indonesia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Indonesia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Europe: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Europe: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Germany: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Germany: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: France: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: France: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: United Kingdom: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: United Kingdom: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Italy: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Italy: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Spain: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Spain: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Russia: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Russia: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Latin America: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Latin America: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Brazil: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Brazil: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Mexico: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Mexico: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Others: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Others: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Middle East and Africa: MRSA Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 91: Middle East and Africa: MRSA Drugs Market: Breakup by Country (in %), 2023
  • Figure 92: Middle East and Africa: MRSA Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 93: Global: MRSA Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 94: Global: MRSA Drugs Industry: Value Chain Analysis
  • Figure 95: Global: MRSA Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: MRSA Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: MRSA Drugs Market Forecast: Breakup by MRSA Type (in Million US$), 2024-2032
  • Table 3: Global: MRSA Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: MRSA Drugs Market Forecast: Breakup by Disease Indication (in Million US$), 2024-2032
  • Table 5: Global: MRSA Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 6: Global: MRSA Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 7: Global: MRSA Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 8: Global: MRSA Drugs Market: Competitive Structure
  • Table 9: Global: MRSA Drugs Market: Key Players
目次
Product Code: SR112024A6905

Abstract

The global MRSA drugs market size reached US$ 3.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.0 Billion by 2032, exhibiting a growth rate (CAGR) of 3.11% during 2024-2032. The rising prevalence of antibiotic resistant strains development, continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission and the growing number of clinical trials represent some of the key factors driving the market.

Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of staphylococcus aureus that generally occurs in patients who undergo surgical procedures, receive intravenous tubing, or come in contact with each other skin-to-skin. The MRSA drugs are used as antimicrobial agents against methicillin-resistant staphylococcus aureus infection in order to kill or restrain it. They inhibit the actions of pathogens while enhancing the patient's cellular synthesis and immunity. The most common MRSA drugs consist of trimethoprim-sulfamethoxazole, clindamycin, minocycline, linezolid, or doxycycline. These drugs are generally used as oral medication, usually on a course of seven to ten days. MRSA infections can arise from hospitals or from community, hence the treatment for MRSA can sometimes involve the administration of oral medications and intravenous (IV) medications, depending on the severity. There are a wide variety of MRSA drugs available that can be used for the treatment of different types of infections, including skin infections, bone infections, bacteremia, and even zoonotic infections in animals.

MRSA Drugs Market Trends:

The rising prevalence of antibiotic resistant strains development among the masses is a significant factor driving the growth of the market. This can be attributed to the increase in the number of cases of hospital-acquired infections (HAIs) on the global level. Also, the continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission is resulting in the development of secondary nosocomial infections, thereby propelling the market. In addition to this, the growing geriatric population that is more susceptible to developing MRSA infections is providing an impetus to the market. Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs. In line with this, numerous product innovations, growing number of clinical trials and the introduction of novel drug variants are creating lucrative growth opportunities in the market. However, the high costs involved in developing novel MRSA drug variants is acting as major growth restraining-factor for the market. On the contrary, continual technological developments in various diagnostic tools, along with the increasing number of clinical trial programs for the screening of antibiotic resistant strains of bacteria, are creating a positive market outlook. The market is further impelled by extensive research and development (R&D) activities conducted by the key players. Some of the other factors contributing to the market include the emergence of generic drugs against presently available products, easy availability of antibiotics across online and offline organized platforms, rapid urbanization, and increasing medical expenditure.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global MRSA drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on MRSA type, drug class, disease indication, route of administration, and distribution channel.

MRSA Type Insights

Hospital-Acquired (HA-MRSA)

Community-Acquired (CA-MRSA)

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the MRSA type. This includes Hospital-Acquired (HA-MRSA) and Community-Acquired (CA-MRSA). According to the report, Hospital-Acquired (HA-MRSA) represented the largest segment.

Drug Class Insights

Lipopeptides

Oxazolidinones

Cephalosporin

Tetracycline

Folate Antagonist

Others

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the drug class. This includes lipopeptides, oxazolidinones, cephalosporin, tetracycline, folate antagonist, and others. According to the report, lipopeptides represented the largest segment.

Disease Indication Insights

Skin Infections

Bone and Joint Infections

Bacteremia

Animal Infections

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the disease indication. This includes skin infections, bone and joint infections, bacteremia, and animal infections. According to the report, skin Infections represented the largest segment.

Route of Administration Insights

Oral Administration

Parenteral Administration

The report has provided a detailed breakup and analysis of the MRSA drugs market based on the route of administration. This includes oral administration and parenteral administration. According to the report, parenteral administration represented the largest segment.

Distribution Channel Insights

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the MRSA drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for MRSA drugs. Some of the factors driving the North America MRSA drugs market include the rising medical expenditure, the increasing number of clinical trial programs, extensive research and development (R&D) activities conducted by key players, etc.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global MRSA drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., Pfizer Inc, etc.

Key Questions Answered in This Report:

  • How has the global MRSA drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global MRSA drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive MRSA drugs markets?
  • What is the breakup of the market based on the MRSA type?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the disease indication?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What is the competitive structure of the global MRSA drugs market?
  • Who are the key players/companies in the global MRSA drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global MRSA Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by MRSA Type

  • 6.1 Hospital-Acquired (HA-MRSA)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Community-Acquired (CA-MRSA)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Lipopeptides
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oxazolidinones
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cephalosporin
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Tetracycline
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Folate Antagonist
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Disease Indication

  • 8.1 Skin Infections
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Bone and Joint Infections
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Bacteremia
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Animal Infections
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral Administration
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral Administration
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

  • 12.1 Overview
  • 12.2 Drivers
  • 12.3 Restraints
  • 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Basilea Pharmaceutica Ltd
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 Crystal Genomics Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
    • 16.3.4 Cumberland Pharmaceuticals Inc
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Melinta Therapeutics Inc
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
    • 16.3.6 Paratek Pharmaceuticals, Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Pfizer Inc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis